4/A
Changes in Ownership
Candel Therapeutics, Inc. Filed Acc 0000950170-25-042724
Chief Technology Officer sold 31,278 shares at $8.82 ($275,947)
- Chief Technology Officer acquired 20,000 shares (option exercise)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
Table I: Non-derivative
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Tyagarajan Seshu Chief Technology Officer | 2025-03-17 | Option exercise 10b5-1 | +20,000 | $1.29 | $25,800 | 116,790 | D: show line 1 in the form |
| Tyagarajan Seshu Chief Technology Officer | 2025-03-17 | Sale 10b5-1 | −31,278 | $8.82 | $275,947 | 85,512 | D: show line 2 in the form |
| Open-market sales · 31,278 sh · avg $8.82 · $275,947 | |||||||
Table II: Derivative
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Tyagarajan Seshu Chief Technology Officer | 2025-03-17 | Option exercise · Stock Option (Right to Buy) 10b5-1 | −20,000 | 70,000 | D: show line 3 in the form |
Loading xslF345X05/ownership.xml…